Hennion & Walsh Asset Management Inc. Purchases 1,553,672 Shares of Ocugen, Inc. $OCGN

Hennion & Walsh Asset Management Inc. boosted its holdings in shares of Ocugen, Inc. (NASDAQ:OCGN) by 121.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,830,397 shares of the company’s stock after buying an additional 1,553,672 shares during the period. Hennion & Walsh Asset Management Inc. owned about 0.84% of Ocugen worth $4,331,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. SmartHarvest Portfolios LLC bought a new position in shares of Ocugen during the 4th quarter worth about $31,000. CTC Alternative Strategies Ltd. bought a new stake in Ocugen in the first quarter valued at about $34,000. BNP Paribas Financial Markets increased its stake in Ocugen by 56.7% in the second quarter. BNP Paribas Financial Markets now owns 36,822 shares of the company’s stock valued at $36,000 after acquiring an additional 13,326 shares during the period. NewEdge Advisors LLC raised its position in Ocugen by 198.0% in the second quarter. NewEdge Advisors LLC now owns 36,814 shares of the company’s stock worth $36,000 after purchasing an additional 24,460 shares in the last quarter. Finally, Schonfeld Strategic Advisors LLC acquired a new position in Ocugen in the fourth quarter worth about $38,000. Institutional investors own 10.27% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on OCGN shares. Wall Street Zen cut shares of Ocugen from a “hold” rating to a “sell” rating in a research note on Saturday. Canaccord Genuity Group lowered their price objective on Ocugen from $12.00 to $11.00 and set a “buy” rating on the stock in a research note on Wednesday, May 27th. Finally, Weiss Ratings cut Ocugen from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 23rd. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $9.50.

Insider Buying and Selling at Ocugen

In other news, CFO Treerita Essali Johnson-Greene acquired 21,000 shares of the company’s stock in a transaction dated Monday, June 15th. The stock was bought at an average price of $1.23 per share, with a total value of $25,830.00. Following the completion of the acquisition, the chief financial officer owned 521,000 shares in the company, valued at approximately $640,830. This represents a 4.20% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 3.95% of the company’s stock.

Key Stories Impacting Ocugen

Here are the key news stories impacting Ocugen this week:

• Positive Sentiment: The FDA cleared Ocugen to begin the Phase 3 OCU410 trial for geographic atrophy associated with dry age-related macular degeneration. The program also received Regenerative Medicine Advanced Therapy designation, potentially enabling priority review and accelerated approval. Ocugen targets three BLAs by 2028
• Positive Sentiment: Ocugen completed a $130 million convertible-notes financing, using roughly $32.7 million to retire higher-cost Avenue Capital debt and extending its expected cash runway into 2028. Cash and restricted cash totaled $100.4 million at June 30. Ocugen second-quarter business update
• Positive Sentiment: The company reported progress across its late-stage pipeline: OCU410 Phase 3 is expected to start this quarter, OCU400 enrollment is complete with topline data expected in the first quarter of 2027, and OCU410ST data are anticipated in the second quarter of 2027. Ocugen Q2 2026 earnings call highlights
• Positive Sentiment: A proposed OCU400 licensing arrangement for the Middle East and North Africa could provide up to $255 million in sales milestones, royalties of 22% on net sales, and an upfront payment. Ocugen reports Q2 results and advances OCU410
• Neutral Sentiment: Second-quarter revenue was $1.49 million, above the $0.89 million analyst estimate, but remains small relative to the company’s development costs. Ocugen reports Q2 loss and beats revenue estimates
• Negative Sentiment: Ocugen’s quarterly loss widened to $0.07 per share from $0.05 a year earlier, missing the $0.05 consensus estimate. Research and development spending rose to $10.7 million, pushing total operating expenses to $17.9 million. Ocugen Q2 earnings miss as R&D costs rise
• Negative Sentiment: The financing improves liquidity but adds convertible debt and potential future share dilution. Ocugen also reported a $24.9 million net loss for the quarter and an accumulated deficit of $452.1 million, underscoring its ongoing dependence on capital markets.

Ocugen Stock Down 0.8%

OCGN opened at $1.27 on Monday. The firm has a market cap of $430.67 million, a price-to-earnings ratio of -4.88 and a beta of 2.21. The company has a debt-to-equity ratio of 4.17, a quick ratio of 0.80 and a current ratio of 0.80. The firm’s 50-day simple moving average is $1.34 and its 200-day simple moving average is $1.56. Ocugen, Inc. has a twelve month low of $0.96 and a twelve month high of $2.73.

Ocugen (NASDAQ:OCGN) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.02). The company had revenue of $1.49 million for the quarter, compared to analysts’ expectations of $0.89 million. Equities research analysts anticipate that Ocugen, Inc. will post -0.22 EPS for the current fiscal year.

Ocugen Company Profile

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.